National Fecal Microbiota Transplant (FMT) Registry
Official title: Fecal Microbiota Transplant National Registry
Funded at American Gastroenterological Assn/inst · NIH-11394403 · Data updated 2026-11-12
This registry collects health and safety information from people who receive fecal microbiota transplants or related live-microbe treatments to help patients with recurrent or severe C. difficile infection.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | American Gastroenterological Assn/inst NIH-funded |
| Lab location | 1 site (Bethesda, United States) |
| Project start | August 4, 2016 |
| Project end | April 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $670,830 |
| NIH project number | 5R24AI118629-10 |
| Project ID | NIH-11394403 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal participants are people treated with or planning to receive fecal microbiota transplant or live biotherapeutic products, especially those with recurrent, severe, or fulminant C. difficile infection.
✕Less likely to help
People without C. difficile infection or who are not receiving FMT or related microbiome therapies are unlikely to gain direct benefit from this registry.
What this research studies
You can join if you've had or are planning to have an FMT or a live biotherapeutic product; sites across North America enroll participants. The registry collects medical history, treatment details, and follow-up information using medical record review, regular questionnaires, and sometimes stool or other samples. Researchers track short-term outcomes like infections and procedure results as well as long-term health effects that might appear years later. The goal is to identify rare risks, improve donor and product screening, and guide safer care for people with C. difficile.
Why it matters
Potential benefit: If successful, the registry could make FMT and similar therapies safer and more effective by identifying rare infections, long-term effects, and best practices for screening and treatment.
How similar studies have gone: FMT is already effective for treating recurrent C. difficile infection, but recent reports of transmitted multidrug-resistant organisms and other pathogens mean ongoing registry data are needed to understand and prevent rare harms.
Where this research is happening
-
American Gastroenterological Assn/inst
Bethesda, United States Active
Researchers
- Principal investigator: Wu, Gary D. — American Gastroenterological Assn/inst
- Study coordinator: Wu, Gary D.
Related research
Other NIH-funded projects on the same topics.
-
Vaginal microbiota transplant to promote Lactobacillus-dominant cervicovaginal communities
A clinical trial tests whether transferring vaginal microbiota from healthy donors can establish Lactobacillus-dominant vaginal communities to reduce risks linked with bacterial vaginosis.
-
Fecal transplant to help alcohol-related liver disease
A clinical trial will test whether a standardized oral fecal microbiota transplant (FMT) capsule can help people with alcohol-related liver disease drink less and feel mentally better.
-
Gut Restore-PAH: Microbiota Transplant to Help Pulmonary Angiopathy
A small pilot study will test whether transplanting healthy gut bacteria, with antibiotics beforehand and fiber support, can help people with pulmonary arterial hypertension.
-
Microbiota Transplant Therapy to Prevent HE Recurrence in Veterans with Cirrhosis
A Phase 2B multi-center study tests using donor microbiota transplants to prevent hepatic encephalopathy from coming back in Veterans with cirrhosis.
-
Understanding how Fecal Microbiota Transplant helps with C. difficile infection
This project aims to discover how fecal microbiota transplant (FMT) works to prevent C. difficile infections from coming back in patients.
-
Vaginal transplant to restore Lactobacillus-dominant vaginal communities
This trial tests whether placing healthy donor vaginal bacteria into people with recurrent bacterial vaginosis helps restore Lactobacillus-dominant vaginal communities.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.